Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more
Nanjing Vazyme Biotech Co Ltd (688105) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.020x
Based on the latest financial reports, Nanjing Vazyme Biotech Co Ltd (688105) has a cash flow conversion efficiency ratio of 0.020x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥75.30 Million) by net assets (CN¥3.84 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nanjing Vazyme Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Nanjing Vazyme Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Nanjing Vazyme Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nanjing Vazyme Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shandong Sinobioway Biomedicine Co Ltd
SHE:002581
|
-0.043x |
|
Baota Industry Co Ltd
SHE:000595
|
0.311x |
|
BELRISE INDUSTRIES LTD
NSE:BELRISE
|
0.011x |
|
EQUITY BANCSHS A DL -01
F:44X
|
N/A |
|
Lotte Energy Materials Corporation
KO:020150
|
-0.008x |
|
Yunding Technology Co Ltd
SHE:000409
|
-0.043x |
|
Jinxi Axle Co Ltd
SHG:600495
|
-0.015x |
|
COHTF
PINK:COHTF
|
N/A |
Annual Cash Flow Conversion Efficiency for Nanjing Vazyme Biotech Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Nanjing Vazyme Biotech Co Ltd from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.94 Billion | CN¥-9.68 Million | -0.002x | -104.99% |
| 2023-12-31 | CN¥4.03 Billion | CN¥198.40 Million | 0.049x | -69.11% |
| 2022-12-31 | CN¥4.61 Billion | CN¥735.17 Million | 0.159x | +6.66% |
| 2021-12-31 | CN¥4.13 Billion | CN¥616.80 Million | 0.149x | -75.22% |
| 2020-12-31 | CN¥1.33 Billion | CN¥803.55 Million | 0.603x | +693.51% |
| 2019-12-31 | CN¥200.02 Million | CN¥15.20 Million | 0.076x | +415.63% |
| 2018-12-31 | CN¥166.08 Million | CN¥-4.00 Million | -0.024x | +5.92% |
| 2017-12-31 | CN¥150.82 Million | CN¥-3.86 Million | -0.026x | -- |